CTLA4 and cancer: CD96, a novel immune checkpoint protein, together with CD226 and TIGIT form a receptors pathway that closely resembles the CD28/CTLA‐4 pathway.[5] CD96 has been shown to function as an important inhibitor of natural killer (NK) and T‐cell activity.[6, 7, 8] Although intracellular signal transduction via CD96 has not been well‐characterized, recent studies have suggested that therapies targeting CD96 can be developed for cancer immunotherapy.